Sjölander A, Baldwin T M, Curtis J M, Handman E
The Walter and Eliza Hall Institute of Medical Research, Post Office Royal Melbourne Hospital, Victoria, Australia.
J Immunol. 1998 Apr 15;160(8):3949-57.
Experimental systems based on immunization with plasmid DNA or immune-stimulating complexes were used to delineate the requirements for generation of protective immunity against murine leishmaniasis. Vaccination with plasmid DNA encoding the host-protective Leishmania major parasite surface Ag-2 primed for an essentially exclusive Th1 response that protected mice against L. major infection. In contrast, parasite surface Ag-2 in immune-stimulating complexes generated an immune response with mixed Th1-like and Th2-like properties that was not protective despite the activation of large numbers of CD4+ T cells secreting IFN-gamma. These results indicate that a Th1 response is sufficient to protect against cutaneous leishmaniasis, but the induction of a simultaneous Th2 response abrogates the Th1 effector function. DNA vaccines may therefore have an advantage for diseases in which protection depends on the induction of Th1 responses.
基于用质粒DNA或免疫刺激复合物免疫的实验系统被用于确定产生针对鼠利什曼病的保护性免疫的要求。用编码宿主保护性利什曼原虫主要寄生虫表面抗原-2的质粒DNA进行疫苗接种引发了基本上排他性的Th1反应,从而保护小鼠免受主要利什曼原虫感染。相比之下,免疫刺激复合物中的寄生虫表面抗原-2产生了具有混合Th1样和Th2样特性的免疫反应,尽管激活了大量分泌IFN-γ的CD4 + T细胞,但该反应并无保护作用。这些结果表明,Th1反应足以预防皮肤利什曼病,但同时诱导Th2反应会消除Th1效应功能。因此,DNA疫苗对于保护依赖于Th1反应诱导的疾病可能具有优势。